2023
Entrant
Category
Client's Name
Country / Region
Unlocking the Proteome -The NULISA™ Platform sets a new standard in proteomic analysis with attomolar sensitivity, allowing for unprecedented biomarker detection and quantitation.
By leveraging a proprietary sequential immunocomplex capture and release mechanism and the latest advances in Next Generation Sequencing (NGS), the NULISA technology provides both ultra-high sensitivity and scalable multiplexing.
Credits
Entrant
ProPharma Group
Category
Provider & Services - Professional Services
Country / Region
United States
Entrant
Courageous Studios
Category
Video, Commercial & Film - Technology / Science
Country / Region
United States
Entrant
The Next Practice
Category
Website - Science / Technology
Country / Region
United States
Entrant
RxSense
Category
Strategic Program - Strategic Program / Others___
Country / Region
United States